Lymphocyte to Procalcitonin Ratio in Covid-19 Patients
1 other identifier
observational
535
1 country
1
Brief Summary
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedFirst Submitted
Initial submission to the registry
September 27, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 27, 2024
CompletedFirst Posted
Study publicly available on registry
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedOctober 3, 2024
October 1, 2024
4.5 years
September 27, 2024
October 1, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
outcome
The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.
30 days
Study Arms (1)
Covid19(+)
Covid19 patients with a positive PCR test
Eligibility Criteria
Patients over 18 years of age who applied to suleyman demirel university emergency department and diagnosed with covid 19 by PCR
You may qualify if:
- Covid19 PCR test positive
You may not qualify if:
- Pregnancy Under 18 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Süleyman demirel üniversitesi tıp fakültesi
Isparta, 32200, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Furkan Ç Oğuzlar, asst. prof.
suleyman demirel university faculty of medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- medical doctor
Study Record Dates
First Submitted
September 27, 2024
First Posted
October 1, 2024
Study Start
April 1, 2020
Primary Completion
September 27, 2024
Study Completion
December 1, 2024
Last Updated
October 3, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share